Alzheimer’s disease has a higher incidence in women. This sex difference was associated with a modification of certain proteins of the immune system. According to a recent study, the drop in estrogen with menopause increased the expression in the brain of a neurotransmitter, nitric oxide (NO), generating the S-nitrosylation of complement factor C3 (abbreviated SNO-C3), which activated the microglia. Read More
Research shows that microglia, macrophage cells found in the central nervous system, are needed to maintain nerve health by preventing the degeneration of the myelin sheath that protects neurons. The study, led by the University of Edinburgh and the University of Toronto and published on Dec. 14, 2022, in Nature, showed microglia could be a potential therapeutic target for neurological conditions involving myelin degeneration. Read More
Symbio Pharmaceuticals Ltd. has entered into a sponsored research agreement with Tufts University to conduct joint research on the intravenous formulation of the antiviral drug brincidofovir. Read More
Shanghai Raising Pharmaceutical Co. Ltd. has synthesized prodrugs of thiamine acting as amyloid-β (Aβ) protein production inhibitors reported to be useful for the treatment of neurodegenerative diseases, preferably Alzheimer's disease (AD). Read More
Shenzhen Chipscreen Biosciences Ltd. has identified heterocyclic compounds acting as thyroid hormone receptor (THR) β agonists expected to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes, obesity, hyperlipidemia, hypothyroidism, atherosclerosis, thyroid cancer and hypercholesterolemia, among others. Read More
Jiangsu Recbio Technology Co. Ltd. has received clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC-610, from the Food and Drug Administration of the Philippines. A phase I trial will be conducted in healthy volunteers. Read More
Pharmablock Sciences (Nanjing) Inc. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of inflammation and autoimmune disease. Read More
Rearrangement of the KMT2A gene is a recurrent mutation in acute myeloid leukemia (AML) that leads to poor outcomes in patients due to increased rate of relapsed and refractory disease. The identification of novel targets and potential therapies is crucial for patients with KMT2A-rearranged leukemias. Read More
The sex-determining region Y (SRY)-related HMG-box, group E (SOXE) transcription factors SOX9 and SOX10 are essential for the specification and differentiation of many progenitor cell types and for the development of several organs and tissues. Read More
Additional early-stage research and drug discovery news in brief, from: Everest Medicines, Lantern Pharma, Providence Therapeutics, Rallybio. Read More
